Tryptophanyl tRNA synthetase antibody
GTX110223
ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
TargetWARS1
Overview
- SupplierGeneTex
- Product NameTryptophanyl tRNA synthetase antibody
- Delivery Days Customer9
- Application Supplier NoteWB: 1:500-1:3000. IHC-P: 1:100-1:1000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration1 mg/ml
- ConjugateUnconjugated
- Gene ID7453
- Target nameWARS1
- Target descriptiontryptophanyl-tRNA synthetase 1
- Target synonymsGAMMA-2, HMN9, HMND9, IFI53, IFP53, NEDMSBA, WARS, tryptophan--tRNA ligase, cytoplasmic, epididymis secretory sperm binding protein, hWRS, interferon-induced protein 53, trpRS, tryptophan tRNA ligase 1, cytoplasmic
- HostRabbit
- IsotypeIgG
- Protein IDP23381
- Protein NameTryptophan--tRNA ligase, cytoplasmic
- Scientific DescriptionAminoacyl-tRNA synthetases catalyze the aminoacylation of tRNA by their cognate amino acid. Because of their central role in linking amino acids with nucleotide triplets contained in tRNAs, aminoacyl-tRNA synthetases are thought to be among the first proteins that appeared in evolution. Two forms of tryptophanyl-tRNA synthetase exist, a cytoplasmic form, named WARS, and a mitochondrial form, named WARS2. Tryptophanyl-tRNA synthetase (WARS) catalyzes the aminoacylation of tRNA(trp) with tryptophan and is induced by interferon. Tryptophanyl-tRNA synthetase belongs to the class I tRNA synthetase family. Four transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Yamashita N, Morimoto Y, Fushimi A, et al. MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer. Mol Cancer Res. 2023,21(3):274-289. doi: 10.1158/1541-7786.MCR-22-0772Read this paper
- Hagiwara M, Fushimi A, Bhattacharya A, et al. MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer. Oncoimmunology. 2022,11(1):2029298. doi: 10.1080/2162402X.2022.2029298Read this paper





